Stock 6576 FORESEE PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Foresee Pharmaceuticals Co., Ltd.

Equities

6576

TW0006576002

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-07-02 pm EDT 		5-day change 1st Jan Change
84.1 TWD -0.24% Intraday chart for Foresee Pharmaceuticals Co., Ltd. -0.24% -12.58%
Jun. 24 Foresee Pharmaceuticals Co., Ltd. announced a financing transaction CI
May. 14 Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • The company's "enterprise value to sales" ratio is among the highest in the world.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
FORESEE PHARMACEUTICALS CO., LTD. Stock Foresee Pharmaceuticals Co., Ltd.
-12.58% 351M -
MODERNA, INC. Stock Moderna, Inc.
+16.59% 44.44B
B-
LONZA GROUP AG Stock Lonza Group AG
+41.42% 39.84B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-10.62% 37.68B
B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.92% 31.46B
B
CELLTRION, INC. Stock Celltrion, Inc.
-9.78% 27.02B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.34% 26.29B
B-
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+41.53% 13.8B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.49% 12.46B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.40% 11.26B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 6576 Stock
  4. Ratings Foresee Pharmaceuticals Co., Ltd.